Medicare Claims Processing Manual

Chapter 17 - Drugs and Biologicals

Crosswalk

New Chap	New Sect	Int. Pub. 13	Carrier Pub 14.	SNF Pub 12	Other Source	Description
17	10		B3-2049, B3-5201		A-00-36, B-01-10, B-01-38, AB-01-16, A-02-129, AB-02-174, AB-03-014	Payment Rules for Drugs and Biologicals
17	20		B3-5202, R1799B3		AB-02-075, PRM 2711.2 B. 2	Payment Allowance Limit for Drugs and Biologicals
17	20.1				AB-02-075, B-03-059, AB-03-047, PRM 2711.2 B. 2	Single Drug Pricer (SDP)
17	20.2		B3-5202.1		AB-02-075, PRM 2711.2 B. 2	Calculation of the AWP
17	20.3		B3-5202.1		AB-02-075, PRM 2711.2 B.2	Detailed Procedures for Determining AWPs and the Drug Payment Allowance Limits
17	20.3.1					Background
17	20.3.2				AB-02-075, PRM 2711.2 B. 2	Review of Sources for Medicare Covered Drugs and Biologicals
17	20.3.3				AB-02-075, PRM 2711.2 B. 2	Use of Generics

New Chap	New Sect	Int. Pub. 13	Carrier Pub 14.	SNF Pub 12	Other Source	Description
17	20.3.4				AB-02-075, PRM 2711.2 B. 2	Find the Strength and Dosage
17	20.3.5				AB-02-075, PRM 2711.2 B. 2	Restrictions
17	20.3.6				AB-02-075, PRM 2711.2 B. 2	Inherent Reasonableness for Drugs and Biologicals
17	20.3.7		B3-5202.2			Injection Services
17	20.3.8		B3-5202.3			Injections Furnished to ESRD Beneficiaries
17	30		B3-5202.1		AB-02-075, PRM 2711.2 B. 2	Carrier Distribution of Limit Amounts
17	40				AB-02-075, PRM 2711.2 B. 2	Discarded Drugs and Biologicals
17	50		B3-5247		PM B-01-15	Assignment Required for Drugs and Biologicals
17	60				PM B-01-02	DMEPOS Suppliers Require a License to Dispense Drugs
17	60.1		B3-4118			Prescription Drugs Billed by Suppliers Not Licensed to Dispense Them
17	70				Staff developed-No Xref	Claims Processing Requirements - General
17	70.1				B-03-041	Billing Drugs Electronically - NCPDP
17	70.1.1				B-03-057	Reporting Modifiers in the Compound Drug Segment
17	70.1.2				B-03-057	Coordination of Benefits (COB)

New Chap	New Sect	Int. Pub. 13	Carrier Pub 14.	SNF Pub 12	Other Source	Description
17	70.1.3				B-03-057	Inbound NCPDP Claim
17	80				Title+Xref-Not in manual	Claims Processing for Special Drug Categories
17	80.1	A3-3660.13		SNF 536.1		Oral Cancer Drugs
17	80.1.1	A3-3660.13		SNF 536.1		HCPCS Service Coding for Oral Cancer Drugs
17	80.1.2	A3-3660.13		SNF 536.1		HCPCS and NDC Reporting for Prodrugs
17	80.1.3	A3-3660.13		SNF 536.1		Other Claims Processing Issues for Oral Cancer Drug
17	80.1.4	A3-3660.13		SNF 536.1		MSN/ANSI X12N Message Codes for Oral Cancer Drug Denials
17	80.2	A3-3660.15	B3-4460		PM A-98-5	Oral Anti-Emetic Drugs Used as Full Replacement for Intravenous Anti-Emetic Drugs as Part of a Cancer Chemotherapeutic Regimen
17	80.2.1	A3-3660.15	B3-4460		PM A-98-5	HCPCS Codes for Oral Anti-Emetic Drugs
17	80.2.2	A3-3660.15	B3-4460		PM A-98-5	Claims Processing Jurisdiction for Oral Anti-Emetic Drugs
17	80.2.3	A3-3660.15	B3-4460		PM A-98-5	MSN /ANSI X12N Denial Messages for Anti-Emetic Drugs
17	80.3		B3-4471		PM AB-01-10	Billing for Immunosuppressive Drugs
17	80.3.1	A3-3660.8				Requirements for Billing FI for Immunosuppressive Drugs

New Chap	New Sect	Int. Pub. 13	Carrier Pub 14.	SNF Pub 12	Other Source	Description
17	80.3.2					MSN/Remittance Messages for Immunosuppressive Drugs
17	80.4		B3-5245		PM AB-00-117, AB-03-014	Billing for Hemophilia Clotting Factors
17	80.5	A3-3660.11, A3-3660.12		SNF 536.1	PM AB-02-72	Self-Administered Drugs
17	90				Title-No Xref	Claims Processing Rules for Hospital Outpatient Billing and Payment
17	90.1				PM-A-00-42, A-00-61, A-01-50	Blood/Blood Products and Drugs Classified in Separate APCs for Hospital Outpatients
17	90.2				A-02-026	Changes to Pass-Through Drugs and Biologicals Final Rule
17	90.2.1				PM A-02-026, §IX.A	HCPCS Codes Replacements
17	90.2.2				PM-A-02-026 §IX.B	Codes Not Recognized for Medicare Under the Hospital OPPS
17	90.2.3				PM-A-02-026 §IX.C	Additional Drugs Eligible for Pass-Through Payments
17	90.2.4				PM-A-02-026 §IX.D	Changes to Payment Rates and Co-Pay From the March 1, 2002 OPPS Final Rule
17	90.2.5				PM-A-02-026 §IX.E	Additional Corrections
17	90.2.6				PM-A-02-026 §IX.F	Additional Billing and Reporting Information Related to Pass-Through Drugs Effective April 1, 200

New Chap	New Sect	Int. Pub. 13	Carrier Pub 14.	SNF Pub 12	Other Source	Description
17	90.2.7				PM-A-02-026 §IX.G	Typographical Errors from the March 1, 2002, OPPS Final Rule
17	90.2.8				PM-A-02-026 §IX.H	Correction to 2003 HCPCS Code Books
17	90.2.9				PM-A-02-026 §X	Pro-Rata Reduction in Drug and Device Pass-Through Payments